Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 2/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 3/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274874 | 0.92 | IRAK1 (0.42) | IRAK1IRAK4RIPK2GPR84GRIN1 | |
| SCHEMBL13280503 | 0.90 | IRAK4 (0.38) | IRAK1IRAK4GPR84METNQO2 | |
| SCHEMBL2268753 | 0.88 | MET (0.43) | IRAK1IRAK4METNQO2 | |
| SCHEMBL2362911 | 0.88 | IRAK4 (0.37) | IRAK1IRAK4RIPK2GPR84GRIN1 | |
| SCHEMBL13275328 | 0.88 | MET (0.41) | IRAK1IRAK4RIPK2METNQO2 | |
| SCHEMBL13275150 | 0.86 | IRAK1 (0.42) | IRAK1IRAK4METNQO2FGFR1 | |
| SCHEMBL13274944 | 0.86 | IRAK1 (0.39) | IRAK1IRAK4CHRM1 | |
| SCHEMBL13274508 | 0.85 | CHRM1 (0.47) | IRAK1ALDH1A1CHRM1 | |
| SCHEMBL13275267 | 0.85 | IRAK1 (0.39) | IRAK1IRAK4ALDH1A1CHRM1 | |
| SCHEMBL164227 | 0.85 | BRD4 (0.37) | IRAK1IRAK4METNQO2FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | IRAK1 584/4885IRAK4 629/4885RIPK2 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.